Single-stage or two-stage: what the difference means for you

For most patients weighing up cartilage restoration options, the most immediate practical question is not about biology — it is about how many times you need to go under anaesthetic. AMIC and MACI both aim to repair focal cartilage defects in the knee, but they follow fundamentally different paths to get there.

AMIC (Autologous Matrix-Induced Chondrogenesis) is completed in a single operation. The surgeon creates tiny perforations in the bone beneath the defect — a technique called microfracture — releasing bone-marrow stem cells that begin forming a repair clot. A bilayered collagen membrane (Chondro-Gide®) is then placed over the defect in the same sitting, stabilising that clot and guiding the incoming cells towards cartilage-like tissue. No prior biopsy or laboratory work is required.

MACI (Matrix-Induced Autologous Chondrocyte Implantation) requires two separate procedures. In the first, a small cartilage sample is taken from your knee and sent to a laboratory, where your own chondrocytes are expanded over a period of weeks. In the second operation — typically three to six weeks later — those cultured cells, seeded onto a collagen scaffold, are implanted into the defect.

The extra stage in MACI adds waiting time and a second episode of surgery, but it delivers a population of true cartilage cells rather than relying on recruited progenitor cells from bone marrow. Whether that biological difference translates into a meaningfully better outcome for a given patient depends largely on the size and characteristics of the defect — the key decision factor explored further in this article.

How AMIC works

The Chondro-Gide® membrane addresses a well-documented limitation of microfracture performed alone. Without a covering scaffold, the marrow clot that forms after subchondral bone perforation is mechanically fragile and prone to displacement during early healing — which helps explain why Kreuz et al. recorded significant score deterioration between 18 and 36 months post-operatively, and why Solheim et al. found less than 60% survivorship at three years after standalone microfracture, with a mean time to failure of just four years.

By holding the clot firmly within the defect and providing an organised scaffold, the membrane creates conditions that favour more durable, hyaline-like repair tissue rather than the weaker fibrocartilage that forms when the clot is left unsupported. In theatre, a shaped aluminium template is used to cut the membrane to fit precisely before it is secured using a press-fit technique approximately 2 mm below the articular surface — all within the same operative episode as the microfracture itself.

Published registry evidence supports the approach for medium-sized defects. The AMIC Registry (Gille et al., 57 patients; mean age 37.3 years; mean defect 3.4 cm²) recorded significant reductions in VAS pain scores (p < 0.001) and meaningful functional gains sustained at both one and two years post-operatively. A retrospective cohort by Schiavoni Panni et al. (21 patients, defects greater than 2 cm²) found continued benefit at seven years — currently the longest available follow-up for AMIC, though the small sample size means this longer-term picture warrants cautious interpretation.

The evidence base is strongest for defects in the region of 2–4 cm². For larger lesions, published data are thinner, and cell-based alternatives carry a more substantial evidence case at present.

How MACI works

MACI begins not in an operating theatre but in a laboratory. At the first stage — a short arthroscopic procedure — the surgeon takes a small biopsy of healthy cartilage, typically from a non-load-bearing region of the knee. That sample is sent to a specialist laboratory, where the patient's own chondrocytes are isolated and expanded in culture over several weeks. The result is a population of living cartilage cells seeded onto a Type I/III collagen membrane, ready for implantation.

At the second operation, the prepared defect is cleaned and the cell-laden scaffold is fixed into position. Because the implant carries actual chondrocytes rather than recruited progenitor cells, it has the biological capacity to produce type II collagen and proteoglycans — the structural components of native hyaline cartilage — rather than the fibrocartilage that typically forms after marrow stimulation alone. How reliably this translates into superior tissue quality has not been fully quantified in direct head-to-head comparisons, though it represents a clear mechanistic distinction from AMIC.

The clinical evidence is anchored by the SUMMIT RCT, which found significantly improved KOOS pain and function scores versus microfracture for defects of 3 cm² or larger at both two- and five-year follow-up. Durability data from a minimum ten-year outcome study by Minas et al. further support the longevity of cell-based repair in appropriately selected patients.

The two-stage process requires additional planning — and access to specialist laboratory infrastructure that is not available at every facility. Patients and referring clinicians should confirm this pathway is in place before committing to the approach.

Why defect size is the starting point

Defect area — measured on MRI and verified arthroscopically at the time of surgery — is the most consistent clinical separator between the two approaches in the published literature.

For smaller focal lesions, broadly under 2 cm², marrow stimulation has historically been used as a first-line option. AMIC fits here as an augmentation strategy: the collagen membrane is designed to improve the durability of marrow-derived repair tissue, addressing the score deterioration and survivorship problems that the literature on standalone microfracture has documented.

As defect size increases toward and beyond 3 cm², the evidence balance shifts. For lesions at or above this threshold, the SUMMIT RCT provided the clearest support for MACI, demonstrating superiority over microfracture on validated pain and function measures. This is the range where delivering actual chondrocytes — rather than relying on recruited progenitor cells — appears to provide the more durable biological foundation.

AMIC occupies a practical middle ground. Registry and cohort evidence covers mean defect sizes in the 2–4 cm² range, and the Schiavoni Panni series supports continued benefit for defects greater than 2 cm² out to seven years. For lesions appreciably larger than 4 cm², published evidence for AMIC is thinner than for MACI, and clinical practice typically favours the cell-based approach in that range.

These thresholds are clinical guidelines rather than hard cutoffs. Defect geometry, location, and concurrent bone involvement all influence the final decision alongside measured area — which is why intraoperative assessment remains a formal step in the pathway before technique selection is confirmed.

What else shapes the choice

Defect area is the starting point, but a specialist reviewing an MRI and patient history will weigh several other factors before confirming which approach is right. Most of what follows reflects clinical consensus and contextual evidence rather than dedicated comparative trials for each patient sub-group.

Defect location

The published evidence for both AMIC and MACI is concentrated in femoral condyle lesions. Patella and trochlear defects involve different loading patterns and present additional technical demands, so they generally require specific surgical expertise; the evidence base in these locations is narrower than for the condyle.

Bone involvement

When a lesion extends into the subchondral bone — an osteochondral defect — neither AMIC nor MACI is necessarily the right tool. Procedures such as osteochondral autograft transfer (OATS / mosaicplasty) or, for larger posttraumatic lesions, fresh osteochondral allograft may be more appropriate because they restore bone and cartilage together in a single construct.

Prior failed marrow-stimulation procedures

Patients who have undergone microfracture and experienced recurrence are generally considered poor candidates for repeat marrow stimulation. Cell-based repair — MACI — is usually the preferred pathway in this setting, since it bypasses reliance on the marrow clot mechanism.

Age and activity level

Younger, active patients with isolated focal defects are the strongest candidates for cartilage restoration of either type. The registry and trial evidence underpinning both techniques is concentrated in this group, and the goal of delaying or avoiding joint replacement carries particular weight for patients with many active years ahead.

Alignment

Varus or valgus knee deformity concentrates load on any repaired area and can undermine the outcome of either procedure. A specialist will assess whether a corrective osteotomy — carried out at the same time or as a staged step — is needed alongside cartilage repair before a final treatment plan is confirmed.

Recovery timelines and realistic outcomes

Recovery from either procedure follows a broadly similar arc: protected weight-bearing on crutches, progressive physiotherapy toward full load, and graduated return to activity. This arc is not passive — structured rehabilitation directly shapes the quality of repair tissue, and consistent patient commitment is a recognised factor in outcome quality.

The main experiential difference lies in staging. AMIC involves a single operative episode and one recovery process. MACI involves two: a minor arthroscopic biopsy first, then — several weeks later — the implantation surgery and the more demanding rehabilitation that follows it.

Return to high-impact activity is generally guided by protocols spanning 9 to 18 months, irrespective of technique. Precise timelines depend on defect size, location, and individual healing progress — milestones are typically set by the operating surgeon based on joint response rather than fixed calendars.

Fossum et al.'s prospective RCT — the only published head-to-head trial, in 41 patients — found clinically meaningful improvements in both the AMIC and ACI groups, but it was not powered to establish superiority. Full quantitative results are not comprehensively available in published summaries, and no trial has yet settled the comparison at a population level.

For most patients, the practical synthesis is this: AMIC represents a credible single-stage option where defect size sits in the mid-range and limiting operative episodes is a priority; the cell-based rationale for MACI becomes stronger for larger lesions or where prior marrow stimulation has failed. A surgeon experienced in both approaches can weigh those factors against individual anatomy and history. Search MSK lists cartilage repair specialists across the UK who offer AMIC and MACI — the region and specialty filters are a practical way to find one suited to your situation.